In vivo imaging models of bone and brain metastases and pleural carcinomatosis with a novel human EML4-ALK lung cancer cell line

Shigeki Nanjo, Takayuki Nakagawa, Shinji Takeuchi, Kenji Kita, Koji Fukuda, Mitsutoshi Nakada, Hisanori Uehara, Hiroshi Nishihara, Eiji Hara, Hidetaka Uramoto, Fumihiro Tanaka, Seiji Yano

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

EML4-ALK lung cancer accounts for approximately 3-7% of non-small-cell lung cancer cases. To investigate the molecular mechanism underlying tumor progression and targeted drug sensitivity/resistance in EML4-ALK lung cancer, clinically relevant animal models are indispensable. In this study, we found that the lung adenocarcinoma cell line A925L expresses an EML4-ALK gene fusion (variant 5a, E2:A20) and is sensitive to the ALK inhibitors crizotinib and alectinib. We further established highly tumorigenic A925LPE3 cells, which also have the EML4-ALK gene fusion (variant 5a) and are sensitive to ALK inhibitors. By using A925LPE3 cells with luciferase gene transfection, we established in vivo imaging models for pleural carcinomatosis, bone metastasis, and brain metastasis, all of which are significant clinical concerns of advanced EML4-ALK lung cancer. Interestingly, crizotinib caused tumors to shrink in the pleural carcinomatosis model, but not in bone and brain metastasis models, whereas alectinib showed remarkable efficacy in all three models, indicative of the clinical efficacy of these ALK inhibitors. Our in vivo imaging models of multiple organ sites may provide useful resources to analyze further the pathogenesis of EML4-ALK lung cancer and its response and resistance to ALK inhibitors in various organ microenvironments.

Original languageEnglish
Pages (from-to)244-252
Number of pages9
JournalCancer Science
Volume106
Issue number3
DOIs
Publication statusPublished - 2015 Mar 1
Externally publishedYes

Fingerprint

Lung Neoplasms
Neoplasm Metastasis
Carcinoma
Bone and Bones
Cell Line
Gene Fusion
Brain
Luciferases
Drug Resistance
Non-Small Cell Lung Carcinoma
Transfection
Neoplasms
Animal Models
Genes
crizotinib
CH5424802

Keywords

  • Alectinib
  • Bone metastasis
  • Brain metastasis
  • Crizotinib
  • Pleural effusion

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

In vivo imaging models of bone and brain metastases and pleural carcinomatosis with a novel human EML4-ALK lung cancer cell line. / Nanjo, Shigeki; Nakagawa, Takayuki; Takeuchi, Shinji; Kita, Kenji; Fukuda, Koji; Nakada, Mitsutoshi; Uehara, Hisanori; Nishihara, Hiroshi; Hara, Eiji; Uramoto, Hidetaka; Tanaka, Fumihiro; Yano, Seiji.

In: Cancer Science, Vol. 106, No. 3, 01.03.2015, p. 244-252.

Research output: Contribution to journalArticle

Nanjo, S, Nakagawa, T, Takeuchi, S, Kita, K, Fukuda, K, Nakada, M, Uehara, H, Nishihara, H, Hara, E, Uramoto, H, Tanaka, F & Yano, S 2015, 'In vivo imaging models of bone and brain metastases and pleural carcinomatosis with a novel human EML4-ALK lung cancer cell line', Cancer Science, vol. 106, no. 3, pp. 244-252. https://doi.org/10.1111/cas.12600
Nanjo, Shigeki ; Nakagawa, Takayuki ; Takeuchi, Shinji ; Kita, Kenji ; Fukuda, Koji ; Nakada, Mitsutoshi ; Uehara, Hisanori ; Nishihara, Hiroshi ; Hara, Eiji ; Uramoto, Hidetaka ; Tanaka, Fumihiro ; Yano, Seiji. / In vivo imaging models of bone and brain metastases and pleural carcinomatosis with a novel human EML4-ALK lung cancer cell line. In: Cancer Science. 2015 ; Vol. 106, No. 3. pp. 244-252.
@article{45f4fad1db43423c8587afbb50258c26,
title = "In vivo imaging models of bone and brain metastases and pleural carcinomatosis with a novel human EML4-ALK lung cancer cell line",
abstract = "EML4-ALK lung cancer accounts for approximately 3-7{\%} of non-small-cell lung cancer cases. To investigate the molecular mechanism underlying tumor progression and targeted drug sensitivity/resistance in EML4-ALK lung cancer, clinically relevant animal models are indispensable. In this study, we found that the lung adenocarcinoma cell line A925L expresses an EML4-ALK gene fusion (variant 5a, E2:A20) and is sensitive to the ALK inhibitors crizotinib and alectinib. We further established highly tumorigenic A925LPE3 cells, which also have the EML4-ALK gene fusion (variant 5a) and are sensitive to ALK inhibitors. By using A925LPE3 cells with luciferase gene transfection, we established in vivo imaging models for pleural carcinomatosis, bone metastasis, and brain metastasis, all of which are significant clinical concerns of advanced EML4-ALK lung cancer. Interestingly, crizotinib caused tumors to shrink in the pleural carcinomatosis model, but not in bone and brain metastasis models, whereas alectinib showed remarkable efficacy in all three models, indicative of the clinical efficacy of these ALK inhibitors. Our in vivo imaging models of multiple organ sites may provide useful resources to analyze further the pathogenesis of EML4-ALK lung cancer and its response and resistance to ALK inhibitors in various organ microenvironments.",
keywords = "Alectinib, Bone metastasis, Brain metastasis, Crizotinib, Pleural effusion",
author = "Shigeki Nanjo and Takayuki Nakagawa and Shinji Takeuchi and Kenji Kita and Koji Fukuda and Mitsutoshi Nakada and Hisanori Uehara and Hiroshi Nishihara and Eiji Hara and Hidetaka Uramoto and Fumihiro Tanaka and Seiji Yano",
year = "2015",
month = "3",
day = "1",
doi = "10.1111/cas.12600",
language = "English",
volume = "106",
pages = "244--252",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - In vivo imaging models of bone and brain metastases and pleural carcinomatosis with a novel human EML4-ALK lung cancer cell line

AU - Nanjo, Shigeki

AU - Nakagawa, Takayuki

AU - Takeuchi, Shinji

AU - Kita, Kenji

AU - Fukuda, Koji

AU - Nakada, Mitsutoshi

AU - Uehara, Hisanori

AU - Nishihara, Hiroshi

AU - Hara, Eiji

AU - Uramoto, Hidetaka

AU - Tanaka, Fumihiro

AU - Yano, Seiji

PY - 2015/3/1

Y1 - 2015/3/1

N2 - EML4-ALK lung cancer accounts for approximately 3-7% of non-small-cell lung cancer cases. To investigate the molecular mechanism underlying tumor progression and targeted drug sensitivity/resistance in EML4-ALK lung cancer, clinically relevant animal models are indispensable. In this study, we found that the lung adenocarcinoma cell line A925L expresses an EML4-ALK gene fusion (variant 5a, E2:A20) and is sensitive to the ALK inhibitors crizotinib and alectinib. We further established highly tumorigenic A925LPE3 cells, which also have the EML4-ALK gene fusion (variant 5a) and are sensitive to ALK inhibitors. By using A925LPE3 cells with luciferase gene transfection, we established in vivo imaging models for pleural carcinomatosis, bone metastasis, and brain metastasis, all of which are significant clinical concerns of advanced EML4-ALK lung cancer. Interestingly, crizotinib caused tumors to shrink in the pleural carcinomatosis model, but not in bone and brain metastasis models, whereas alectinib showed remarkable efficacy in all three models, indicative of the clinical efficacy of these ALK inhibitors. Our in vivo imaging models of multiple organ sites may provide useful resources to analyze further the pathogenesis of EML4-ALK lung cancer and its response and resistance to ALK inhibitors in various organ microenvironments.

AB - EML4-ALK lung cancer accounts for approximately 3-7% of non-small-cell lung cancer cases. To investigate the molecular mechanism underlying tumor progression and targeted drug sensitivity/resistance in EML4-ALK lung cancer, clinically relevant animal models are indispensable. In this study, we found that the lung adenocarcinoma cell line A925L expresses an EML4-ALK gene fusion (variant 5a, E2:A20) and is sensitive to the ALK inhibitors crizotinib and alectinib. We further established highly tumorigenic A925LPE3 cells, which also have the EML4-ALK gene fusion (variant 5a) and are sensitive to ALK inhibitors. By using A925LPE3 cells with luciferase gene transfection, we established in vivo imaging models for pleural carcinomatosis, bone metastasis, and brain metastasis, all of which are significant clinical concerns of advanced EML4-ALK lung cancer. Interestingly, crizotinib caused tumors to shrink in the pleural carcinomatosis model, but not in bone and brain metastasis models, whereas alectinib showed remarkable efficacy in all three models, indicative of the clinical efficacy of these ALK inhibitors. Our in vivo imaging models of multiple organ sites may provide useful resources to analyze further the pathogenesis of EML4-ALK lung cancer and its response and resistance to ALK inhibitors in various organ microenvironments.

KW - Alectinib

KW - Bone metastasis

KW - Brain metastasis

KW - Crizotinib

KW - Pleural effusion

UR - http://www.scopus.com/inward/record.url?scp=84925699494&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925699494&partnerID=8YFLogxK

U2 - 10.1111/cas.12600

DO - 10.1111/cas.12600

M3 - Article

VL - 106

SP - 244

EP - 252

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 3

ER -